SS-31 Dosing & Reconstitution Guide

The administration of SS-31 is typically conducted via subcutaneous injection, with a frequency of once daily. Research indicates a dose range of 5 to 40 mg per day, aligning with Phase I clinical trials that explored dosages from 0.01 to 0.25 mg/kg. In laboratory settings, protocols commonly employ doses between 10 and 50 mg. The duration of treatment cycles can vary significantly, ranging from 4 to 12 weeks, while clinical trials have extended up to 28 weeks. Consistency in the timing of administration is recommended to maintain stable pharmacokinetic profiles, although specific timing may be adjusted based on the design of the study.

For effective use in research, SS-31 is typically provided in a 30 mg vial. To achieve the desired concentration, reconstitution involves adding 3 mL of sterile water, resulting in a final concentration of 10 mg/mL. This concentration allows for flexibility in dosing while ensuring that researchers can accurately measure and administer the peptide. It is crucial to follow proper laboratory protocols during reconstitution to prevent contamination and ensure the integrity of the peptide solution.

In initial dosing strategies, a titration schedule may be employed to gradually adjust the amount of SS-31 administered. For the first week, a daily dose of 10 mg is commonly utilized. Following this introductory phase, studies have indicated that doses can be increased to a range of 20 to 40 mg per day from the second week onward. This approach allows for monitoring of individual responses and potential side effects, facilitating a more tailored dosing strategy in research contexts.

The storage conditions for SS-31 are critical for maintaining the peptide's stability and efficacy. When lyophilized, SS-31 should be stored at temperatures of -20 °C (-4 °F) to preserve its integrity. Once reconstituted, the peptide must be kept between 2 and 8 °C (35.6–46.4 °F) and is recommended for use within 28 days to ensure optimal performance in research applications. Proper storage practices are essential to prevent degradation and ensure reliable experimental outcomes.

For subcutaneous administration of SS-31, common injection sites include the abdomen and thigh. These sites are selected based on their accessibility and the ability to facilitate consistent absorption. Researchers should consider site rotation to minimize local tissue reactions and optimize the pharmacokinetic profile of the peptide. Understanding the anatomical considerations of these sites can contribute to more effective experimental designs and outcomes.

Clinical trials have generally reported that SS-31 is well-tolerated at the tested doses, with common side effects including mild injection site reactions such as pain and redness. Other reported adverse effects are relatively infrequent and include mild headache, dizziness, and nausea. However, certain contraindications have been noted, particularly regarding the use of SS-31 in pregnant or breastfeeding individuals due to insufficient safety data. Additionally, caution is advised for individuals with severe renal impairment, as pharmacokinetic data in this population is limited. Hypersensitivity to any component of the formulation is also a critical consideration.